Table 1.
Comparison of the national Austrian Society of Surgical Oncology (ASSO) cohort and international multicenter cohort (IMC) of patients undergoing curative intent surgery for pancreatic neuroendocrine neoplasm (panNEN).
| Characteristics | ASSO (n = 160) | IMC (n = 204) | P |
|---|---|---|---|
| Female gender | 76 (47.5%) | 87 (42.6%) | 0.355 |
| Age (years; median; IQR) | 62.4 (53.2; 69.5) | 60.0 (50.0; 67.0) | 0.037 |
| Preoperative symptoms | 0.093 | ||
| No symptoms | 105 (65.6%) | 134 (65.7%) | |
| Pain | 23 (14.4%) | 43 (21.1%) | |
| Others (including jaundice) or multiple | 32 (20.0%) | 27 (13.2%) | |
| Preoperative Bilirubin ≥ 4 mg/dL | 7 (4.4%) | 10 (4.9%) | 0.813 |
| Preoperative CRP (mg/dL; median; IQR) | 0.30 (0.12; 0.69) | 0.25 (0.19; 0.65) | 0.037 |
| Metastases present | 27 (16.9%) | 13 (6.4%) | 0.001 |
| Primary tumor size ≥3 cm | 79 (49.4%) | 84 (41.2%) | 0.118 |
| Tumor location | 0.068 | ||
| Head | 55 (34%) | 81 (39.7%) | |
| Body/Tail | 96 (60.0%) | 120 (58.8%) | |
| Multiple | 9 (5.6%) | 3 (1.5%) | |
| ENETS T-category | 0.003 | ||
| T1/T2 | 90 (56.3%) | 145 (71.1%) | |
| T3/T4 | 70 (43.8%) | 59 (28.9%) | |
| Nodal status | 0.249 | ||
| Nodal-negative | 102 (63.8%) | 114 (55.9%) | |
| Nodal-positive | 40 (25.0%) | 57 (27.9%) | |
| Nodal-status unknown (Nx) | 18 (11.3%) | 33 (16.2%) | |
| Tumor grading (missing: 6) | 0.002 | ||
| G1 | 66 (42.0%) | 120 (59.7%) | |
| G2 | 71 (45.2%) | 68 (33.8%) | |
| G3 | 20 (12.7%) | 13 (6.5%) | |
| R0 resection margin (missing: 3) | 141 (89.8%) | 184 (90.2%) | 0.903 |
| 90-day severe morbidity | 20 (12.5%) | 17 (8.3%) | 0.192 |
| 90-day mortality | 6 (3.8%) | 4 (2.0%) | 0.345 |
| Follow-up for OS (months; median; IQR) | 57.5 (28.3; 83.3) | 38.2 (20.1; 73.2) | 0.006 |
| Death during follow-up | 37 (23.1%) | 27 (13.2%) | 0.014 |
| Estimated 5-yr/10-yr OS after resection * | 80.1%/57% | 89.5%/76.4% | 0.069 |
| Estimated 5-yr/10-yr DSS after resection * | 87.0%/76.9% | 96.5%/90.7% | 0.037 |
| Recurrence during follow-up (missing: 4) | 43 (27.6%) | 43 (21.1%) | 0.153 |
* median not reached in the ASSO cohort, therefore 5/10-year survival is presented. ASSO = Austrian Society of Surgical Oncology; CRP = C-reactive protein; DSS = Disease-specific survival; ENETS = European Neuroendocrine Tumor Society; IMC = International Multicenter Cohort; IQR = Interquartile range; OS = Overall survival; yr = year.